Strand-seq Unlocks Personalized Genomics by Phasing Every Chromosome End-to-End
A powerful single-cell sequencing technique now assigns genetic variants to maternal or paternal chromosomes, transforming rare disease diagnosis.
Summary
Strand-seq is a single-cell DNA sequencing technique that enables chromosome-length phasing — the ability to sort genetic variants onto their correct maternal or paternal chromosomes. Combined with long-read sequencing, it supports near-complete diploid genome assemblies that conventional methods miss. A new Strand-seq-based approach also uses DNA methylation patterns to determine the parent-of-origin for genetic variants, a capability with major implications for diagnosing rare diseases, predicting drug responses, and understanding imprinting disorders. This review by Hanlon and Lansdorp outlines how Strand-seq works and why it represents a significant leap forward for personalized genomics, particularly for the many patients who remain undiagnosed despite standard genome sequencing.
Detailed Summary
Personalized genomics promised to transform medicine by linking individual genetic profiles to disease risk, drug response, and heritable conditions. Genome-wide association studies have made progress, but a persistent gap remains: many patients with rare diseases receive no diagnosis even after full genome sequencing. A major reason is that conventional sequencing struggles to phase genomic variants — that is, to determine which copy of each chromosome carries which mutation.
Strand-seq is a single-cell DNA sequencing technique that addresses this limitation by enabling chromosome-length phasing across the entire genome. When combined with long-read sequencing platforms, Strand-seq supports the construction of diploid genome assemblies that capture nearly all genomic variation, including structural variants, repetitive regions, and complex rearrangements that short-read methods routinely miss.
A key advance highlighted in this review is a new Strand-seq-based method that incorporates DNA methylation data to assign genetic variants not just to haplotypes but specifically to maternally or paternally inherited chromosomes. This parent-of-origin resolution is critical for understanding imprinting disorders, X-linked conditions, and other scenarios where the biological effect of a variant depends on which parent transmitted it.
The implications for longevity and aging medicine are meaningful. More complete and phased personal genomes could improve identification of rare variants linked to accelerated aging, neurodegeneration, or cancer predisposition. Parent-of-origin-aware analysis may also clarify why individuals with identical mutations show different disease trajectories.
Caveats include that this is a review article based on existing data, not a new clinical trial. Strand-seq requires specialized laboratory expertise and computational infrastructure. Broader clinical adoption will depend on cost reduction and workflow standardization. Conflicts of interest are noted, as authors hold patents and equity in companies commercializing related technologies.
Key Findings
- Strand-seq enables chromosome-length phasing, resolving variants missed by conventional short-read sequencing.
- Combined with long-read data, Strand-seq supports near-complete diploid personal genome assemblies.
- A new method uses DNA methylation to assign variants to specific maternal or paternal chromosomes.
- Many rare disease patients remain undiagnosed due to incomplete genomic phasing in standard sequencing.
- Parent-of-origin-aware genome analysis represents a new frontier for personalized and precision medicine.
Methodology
This is a narrative review article summarizing the principles and applications of Strand-seq, a single-cell DNA sequencing technique. The authors synthesize existing literature on chromosome-length phasing, diploid genome assembly, and methylation-based parent-of-origin assignment. No new clinical trial or cohort data is presented.
Study Limitations
This is a review article and does not present new experimental or clinical outcome data. Authors have disclosed financial interests in companies commercializing Strand-seq-related technologies, which may introduce bias. Clinical adoption remains limited by technical complexity, cost, and the need for specialized bioinformatics pipelines.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: